Targeting CD47-SIRPα axis still shows promise in solid tumours
Researchers presented early-phase clinical trial results for two novel fusion proteins, HCB101 and HCB301, designed to target the CD47-SIRPα axis in solid tumors. These agents demonstrated reduced hematological toxicity compared to previous treatments while showing potential for tumor regression.
Why it matters
Overcoming treatment-limiting cytopenias is a critical hurdle in developing CD47-targeting cancer therapies, which could offer new options for heavily pre-treated patients.
Audience during the ESMO Targeted Anticancer Therapies Asia Congress 2026 (12 - 14 June, Hong Kong, SAR, China)
The article reports on clinical trial data from a medical conference without emotive language or political framing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in